This post has been archived and contains information that may be out of date.
CHA has submitted comments on the Centers for Medicare & Medicaid Services’ proposed rule updating policies for the contract year 2023 Medicare Advantage (MA) and Medicare prescription drug benefit programs.
In the letter, CHA limited comments to proposals related to improving experiences for dual eligible individuals, which were informed by member experiences under the earlier dual demonstration Cal MediConnect.
In addition, CHA commented on the agency’s request for information on MA plan prior authorization policies for hospital transfers to post-acute care settings during the COVID-19 public health emergency.
